

Formulation	Trade Name	Coverage
Long-Acting Stimulants	<p>Adderal XR</p> <p>Biphentin</p> <p>Concerta</p> <p>MPH ER / ER-C</p> <p>For individuals diagnosed with attention deficit hyperactivity disorder (ADHD) who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following criteria: 1) Demonstrate significant and problematic disruptive behaviour, or who have problems with inattention that interfere with learning, and 2) Have been tried on immediate release or slow-release methylphenidate with unsatisfactory results. Requests will be considered from prescribers with expertise in ADHD.</p> <p>Vyvanse – 60 mg max</p> <p>For the treatment of attention deficit hyperactivity disorder (ADHD) in patients who: 1) demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning; and 2) have been tried on methylphenidate (immediate release or long-acting formulation) or dexamphetamine with unsatisfactory results. Requests will be considered from prescribers with expertise in ADHD.</p>	<p>Covered – No Restrictions</p> <p>Special Authorization</p>
	Foquest	Not Covered
Short Acting Stimulants	<p>Ritalin</p> <p>Ritalin SR</p> <p>Dexedrine</p> <p>Dexedrine Spansules</p>	Covered – No Restrictions
Non-Stimulant Medications	<p>Strattera</p> <p>Intuniv XR</p>	<p>Covered – No Restrictions</p> <p>Not Covered</p>

Information retrieved from the province of Nova Scotia in June 2020, [click here](#) to access the most up to date coverage information. [Special Authorization](#) form must be submitted by mail or fax. for more information on special authorization, [click here](#).